ZA200606083B - Anti-epcam immunoglobulins - Google Patents
Anti-epcam immunoglobulins Download PDFInfo
- Publication number
- ZA200606083B ZA200606083B ZA200606083A ZA200606083A ZA200606083B ZA 200606083 B ZA200606083 B ZA 200606083B ZA 200606083 A ZA200606083 A ZA 200606083A ZA 200606083 A ZA200606083 A ZA 200606083A ZA 200606083 B ZA200606083 B ZA 200606083B
- Authority
- ZA
- South Africa
- Prior art keywords
- cancer
- immunoglobulin
- epcam
- administration
- serum
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 165
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 165
- 229940072221 immunoglobulins Drugs 0.000 title description 5
- 210000002966 serum Anatomy 0.000 claims abstract description 107
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims abstract description 67
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims abstract description 66
- 238000000034 method Methods 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
- 201000010099 disease Diseases 0.000 claims abstract description 34
- 239000000427 antigen Substances 0.000 claims abstract description 17
- 102000036639 antigens Human genes 0.000 claims abstract description 17
- 108091007433 antigens Proteins 0.000 claims abstract description 17
- 230000001747 exhibiting effect Effects 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 26
- 230000001225 therapeutic effect Effects 0.000 claims description 25
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 22
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 22
- 238000004088 simulation Methods 0.000 claims description 19
- 230000037396 body weight Effects 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 11
- 238000001990 intravenous administration Methods 0.000 claims description 11
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000029742 colonic neoplasm Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 201000010175 gallbladder cancer Diseases 0.000 claims description 5
- 210000004907 gland Anatomy 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 210000000813 small intestine Anatomy 0.000 claims description 5
- 210000001685 thyroid gland Anatomy 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 230000002085 persistent effect Effects 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 24
- 230000014509 gene expression Effects 0.000 description 23
- 230000002411 adverse Effects 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 238000011282 treatment Methods 0.000 description 15
- 238000010186 staining Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 13
- 102000003781 Inhibitor of growth protein 1 Human genes 0.000 description 12
- 108090000191 Inhibitor of growth protein 1 Proteins 0.000 description 12
- 231100000331 toxic Toxicity 0.000 description 12
- 230000002588 toxic effect Effects 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 238000012423 maintenance Methods 0.000 description 10
- 238000001802 infusion Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 8
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 208000019423 liver disease Diseases 0.000 description 7
- 230000003041 necroinflammatory effect Effects 0.000 description 7
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000011260 co-administration Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 208000007660 Residual Neoplasm Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 208000006154 Chronic hepatitis C Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 3
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 208000037844 advanced solid tumor Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 208000010710 hepatitis C virus infection Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000037843 metastatic solid tumor Diseases 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 238000011285 therapeutic regimen Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 102000000989 Complement System Proteins Human genes 0.000 description 2
- 108010069112 Complement System Proteins Proteins 0.000 description 2
- 102000006311 Cyclin D1 Human genes 0.000 description 2
- 108010058546 Cyclin D1 Proteins 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108090000848 Ubiquitin Proteins 0.000 description 2
- 102000044159 Ubiquitin Human genes 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000269627 Amphiuma means Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241001645982 Crax Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710147220 Ent-copalyl diphosphate synthase, chloroplastic Proteins 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/778,915 US20050180979A1 (en) | 2004-02-13 | 2004-02-13 | Anti-EpCAM immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200606083B true ZA200606083B (en) | 2007-10-31 |
Family
ID=34838270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200606083A ZA200606083B (en) | 2004-02-13 | 2006-07-21 | Anti-epcam immunoglobulins |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20050180979A1 (es) |
| EP (2) | EP1713830B1 (es) |
| JP (1) | JP5220315B2 (es) |
| KR (1) | KR101236224B1 (es) |
| CN (1) | CN1976951B (es) |
| AT (1) | ATE437186T1 (es) |
| AU (1) | AU2005215874B2 (es) |
| BR (1) | BRPI0507660A (es) |
| CA (1) | CA2555694C (es) |
| DE (1) | DE602005015544D1 (es) |
| DK (1) | DK1713830T3 (es) |
| EA (1) | EA011951B1 (es) |
| ES (1) | ES2328159T3 (es) |
| HK (1) | HK1096103A1 (es) |
| IL (1) | IL177069A (es) |
| MX (1) | MXPA06008942A (es) |
| NO (1) | NO339364B1 (es) |
| NZ (1) | NZ549125A (es) |
| PL (1) | PL1713830T3 (es) |
| PT (1) | PT1713830E (es) |
| SI (1) | SI1713830T1 (es) |
| UA (1) | UA87128C2 (es) |
| WO (1) | WO2005080428A2 (es) |
| ZA (1) | ZA200606083B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5686493B2 (ja) | 2003-01-24 | 2015-03-18 | ユニバーシティ・オブ・ユタＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｕｔａｈ | テロメアの長さを決定することによって死亡の危険性を予測する方法 |
| RU2434640C2 (ru) | 2006-02-09 | 2011-11-27 | Микромет Аг | Лечение метастатического рака молочной железы |
| EP1865001A1 (en) * | 2006-06-08 | 2007-12-12 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Specific protease inhibitors and their use in cancer therapy |
| US20100226922A1 (en) * | 2006-06-08 | 2010-09-09 | Dorothea Maetzel | Specific protease inhibitors and their use in cancer therapy |
| EA023679B1 (ru) * | 2007-04-04 | 2016-06-30 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | АНТИ-EpCAM АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ |
| EP2379747B1 (en) | 2008-12-22 | 2013-07-03 | University of Utah Research Foundation | Monochrome multiplex quantitative pcr |
| JP6048660B2 (ja) * | 2009-09-21 | 2016-12-21 | ランジュ ラルハン | 甲状腺癌を診断および処置するための方法および組成物 |
| WO2013131001A1 (en) * | 2012-03-02 | 2013-09-06 | Academia Sinica | ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF |
| CN103387988B (zh) * | 2012-09-24 | 2016-01-06 | 厦门大学 | 上皮细胞粘附分子的核酸适体EpCAM Ccut及其制备方法 |
| EP2999800B1 (en) | 2013-05-22 | 2019-09-25 | Telomere Diagnostics Inc. | Measures of short telomere abundance |
| CN103275226B (zh) * | 2013-06-09 | 2017-08-29 | 中国科学技术大学 | 特异性抗人上皮细胞粘附分子（EpCAM）的单克隆抗体的制备、鉴定及应用 |
| US9944978B2 (en) | 2014-12-30 | 2018-04-17 | Telomere Diagnostics, Inc. | Multiplex quantitative PCR |
| ES2873846T3 (es) * | 2015-11-19 | 2021-11-04 | Revitope Ltd | Complementación de fragmento de anticuerpo funcional para un sistema de dos componentes para eliminación redirigida de células no deseadas |
| EP3490589A1 (en) | 2016-07-26 | 2019-06-05 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5853697A (en) * | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| PL193780B1 (pl) * | 1997-04-14 | 2007-03-30 | Micromet Ag | Sposób wytwarzania receptora przeciw ludzkim antygenom, ludzkie przeciwciało i środek farmaceutyczny |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CA2446087C (en) * | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
| US20030175268A1 (en) * | 2002-01-11 | 2003-09-18 | Saint-Remy Jean-Marie R. | Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome |
| US20040033543A1 (en) * | 2002-05-20 | 2004-02-19 | Gisela Schwab | Treatment of renal carcinoma using antibodies against the EGFr |
-
2004
- 2004-02-13 US US10/778,915 patent/US20050180979A1/en not_active Abandoned
-
2005
- 2005-02-09 AT AT05707293T patent/ATE437186T1/de active
- 2005-02-09 NZ NZ549125A patent/NZ549125A/en not_active IP Right Cessation
- 2005-02-09 SI SI200530759T patent/SI1713830T1/sl unknown
- 2005-02-09 CA CA2555694A patent/CA2555694C/en not_active Expired - Fee Related
- 2005-02-09 EA EA200601386A patent/EA011951B1/ru not_active IP Right Cessation
- 2005-02-09 JP JP2006552536A patent/JP5220315B2/ja not_active Expired - Fee Related
- 2005-02-09 AU AU2005215874A patent/AU2005215874B2/en not_active Ceased
- 2005-02-09 EP EP05707293A patent/EP1713830B1/en active Active
- 2005-02-09 BR BRPI0507660-9A patent/BRPI0507660A/pt not_active Application Discontinuation
- 2005-02-09 PL PL05707293T patent/PL1713830T3/pl unknown
- 2005-02-09 CN CN2005800099764A patent/CN1976951B/zh not_active Expired - Fee Related
- 2005-02-09 WO PCT/EP2005/001307 patent/WO2005080428A2/en active Application Filing
- 2005-02-09 KR KR1020067016339A patent/KR101236224B1/ko not_active IP Right Cessation
- 2005-02-09 MX MXPA06008942A patent/MXPA06008942A/es active IP Right Grant
- 2005-02-09 EP EP09165284A patent/EP2107071A3/en not_active Withdrawn
- 2005-02-09 US US10/589,450 patent/US20070274982A1/en not_active Abandoned
- 2005-02-09 UA UAA200608985A patent/UA87128C2/ru unknown
- 2005-02-09 PT PT05707293T patent/PT1713830E/pt unknown
- 2005-02-09 ES ES05707293T patent/ES2328159T3/es active Active
- 2005-02-09 DK DK05707293T patent/DK1713830T3/da active
- 2005-02-09 DE DE602005015544T patent/DE602005015544D1/de active Active
-
2006
- 2006-07-21 ZA ZA200606083A patent/ZA200606083B/en unknown
- 2006-07-25 IL IL177069A patent/IL177069A/en not_active IP Right Cessation
- 2006-09-13 NO NO20064136A patent/NO339364B1/no not_active IP Right Cessation
-
2007
- 2007-02-23 HK HK07102075.7A patent/HK1096103A1/xx not_active IP Right Cessation
-
2012
- 2012-06-01 US US13/486,749 patent/US20120294873A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1713830B1 (en) | Anti-epcam immunoglobulins | |
| JP6841656B2 (ja) | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 | |
| JP2021193096A (ja) | Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法 | |
| TWI795347B (zh) | 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌 | |
| CN116098997A (zh) | 通过施用pd-1抑制剂治疗皮肤癌的方法 | |
| KR20190136076A (ko) | 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제 | |
| WO1994022478A1 (en) | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU) | |
| KR20080110987A (ko) | 항-ｅｇｆｒ 및 항-ｈｅｒ２ 항체를 이용하는 조합 요법 | |
| US6733752B1 (en) | Prevention of tumors with monoclonal antibodies against neu | |
| JP7193628B2 (ja) | 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用 | |
| KR20230066392A (ko) | 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 | |
| JP2019517504A (ja) | 難治性ホジキンリンパ腫におけるニボルマブでのｐｄ−１遮断 | |
| JP2023085422A (ja) | 乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ | |
| JP2023554422A (ja) | がんの治療のための多重特異性抗体 | |
| CN111973739B (zh) | 抗pd-l1单克隆抗体治疗癌症的用途 | |
| Qiu et al. | A novel anti-EGFR mAb Ame55 with lower toxicity and better efficacy than cetuximab when combined with irinotecan | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| CN112672759B (zh) | 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 | |
| WO2024041652A1 (en) | Methods of cancer treatment | |
| WO2023198839A2 (en) | Bispecific antibodies against cd3 and cd20 | |
| WO2023164662A1 (en) | Treatment of squamous non small cell lung cancer | |
| WO2022207727A1 (en) | Antibody and use thereof for the treatment of cancer | |
| KR20230093282A (ko) | 폐암에 대한 lag-3 길항제 요법 | |
| WO2023230554A1 (en) | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer | |
| CN116568307A (zh) | 用于肺癌的lag-3拮抗剂疗法 |